New Delhi, March 31 (IANS) India’s bioeconomy is approaching the $200 billion mark, which is a significant milestone in its evolution with a strong policy push and growing innovation pipeline signalling the next phase of growth, according to a report released on Tuesday.The report by Endiya Partners said that the nation’s bioeconomy has expanded sharply from around $10 billion in 2014 to over $195 billion in 2026, now contributing nearly 5 per cent to the GDP.India, long recognised as the ‘P…
Latest regulatory reforms News & Updates
New Delhi, March 24 (IANS) India’s construction industry is likely to see a 3–5 per cent rise in costs across asset classes in 2026 amid rise in labour costs and higher metal prices, a report said on Tuesday.Developers who embrace workforce formalisation, leverage GST savings strategically, and invest in technology adoption will emerge as leaders in this dynamic landscape, the report noted.The report from real estate services firm JLL said material costs showed mixed trend in 2025 as cement,…
Washington, Feb 2 (IANS) Leading US-India business groups welcomed India’s Union Budget 2026–27, saying it reinforces growth, fiscal discipline, and India’s role as a key economic partner for the United States during global uncertainty.US-India Business Council (USIBC) and the US-India Strategic Partnership Forum (USISPF) said the budget underscored India’s commitment to economic growth, resilience, and global competitiveness, while strengthening the foundations for deeper bilateral comm…
New Delhi, Jan 28 (IANS) Union Ministry of Health and Family Welfare on Tuesday notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, which will help reduce drug development timelines, as well as strengthen the clinical research and pharmaceutical development ecosystem.The amendments are aimed at simplifying regulatory processes, reducing approval timelines, and promoting ease of doing business.The regulatory reforms will provide substantial benefits to stakeholders wh…
New Delhi, Dec 25 (IANS)With GST reforms and Research Development Incentive (RDI) Scheme, the year 2025 has been a crucial turning point for Indian pharma, said industry experts on Thursday, while highlighting innovation and increased access as key factors for the sector’s growth in 2026.Indian pharma is standing at a defining moment. In the past 25 years, the industry has grown from $3 billion to $60 billion. The next 25 years will be shaped by innovation, quality, and access.“The year 2025…